GHK: natural skin-repair peptide (copper-binding, found in human blood)

What this is

GHK (glycyl-L-histidyl-L-lysine) is a tiny three-amino-acid peptide that the human body produces naturally and that circulates in plasma, saliva, and urine. Its most notable chemical property is an unusually strong attraction to copper(II) ions — in the body, GHK is believed to exist predominantly bound to copper as the complex GHK-Cu, which is the biologically active form responsible for most observed effects. GHK was first isolated by Loren Pickart in 1973, and plasma levels decline substantially with age, dropping roughly two-fold between the twenties and sixties (Pickart et al. 2015). It is one of the better-characterized peptides in cosmetic and dermatologic science, with decades of published research on skin rejuvenation, wound healing, and collagen production. In skincare and cosmetic formulations it is commonly labeled "copper peptide," "copper tripeptide-1," or "GHK-Cu." The sequence stored here — GHK — is the bare tripeptide backbone; the commercially and biologically relevant species is the copper-chelated complex GHK-Cu, which requires copper loading and is not represented by the three-letter sequence alone.

History

GHK was discovered by Pickart and Thaler (1973) at the University of Washington, who were investigating why plasma from younger donors appeared to restore youthful protein-synthesis activity in older liver tissue. The active factor turned out to be the tripeptide glycyl-L-histidyl-L-lysine, which chelated copper with unusual affinity (Pickart & Thaler 1973, Nature New Biology). Subsequent work over the following decades established that the copper complex — GHK-Cu — is the tissue-remodeling form, and that endogenous plasma GHK declines markedly with age. Through the 1980s and 1990s the compound moved from a plasma curiosity into clinical dermatology, with the company ProCyte commercializing copper-peptide wound-care and cosmetic products. The cosmetic channel has proven the most durable path to market: topical GHK-Cu has been sold as a dermatologic active in creams and serums for more than thirty years. Interest in injectable and compounded systemic forms grew out of the broader peptide-therapy movement of the 2010s, with human data in those categories remaining far behind the topical and preclinical literature.

What it does

GHK-Cu acts as a biological signal that tells tissues to repair and remodel. It stimulates production of collagen (types I and III), decorin, and other structural proteins that keep skin firm and elastic. It attracts immune cells — macrophages and mast cells — to wound sites to accelerate repair, promotes the growth of new blood vessels (angiogenesis), and supports nerve outgrowth. It also has antioxidant and anti-inflammatory effects, and activates cellular cleanup machinery (the ubiquitin-proteasome system) to remove damaged proteins (Pickart et al. 2012). As a result, GHK-Cu is studied both for cosmetic skin aging and for clinical wound-healing applications.

Evidence

• Human: A 12-week randomized controlled trial found that topical copper tripeptide complex applied after CO₂ laser resurfacing accelerated re-epithelialization and improved skin texture compared with control (Archives of Facial Plastic Surgery, 2006). A separate 12-week facial study in 67 women aged 50–59 with mild to advanced photodamage found twice-daily GHK-Cu cream improved skin laxity, clarity, firmness, and appearance, reduced fine lines and coarse wrinkles, and increased skin density (Pickart et al. 2015, BioMed Research International). A pilot study in 16 patients with distal inflammatory bowel disease reported a mean 60% reduction in disease severity after 12 weeks of rectal GHK-Cu treatment, assessed by endoscopic, histopathological, and symptomatic measures (Mao and colleagues 2025, Frontiers in Pharmacology). No large randomized controlled trials for injectable systemic GHK-Cu have been published.
• Animal: GHK-Cu improved healing of ischemic open wounds in rats, with treated wounds showing faster healing and decreased inflammatory markers compared with controls. Liposomal GHK-Cu accelerated scald wound healing in mice by promoting cell proliferation and angiogenesis (published in Wound Repair and Regeneration, 2017). GHK-Cu complex transiently improved healing outcomes in a rat model of ACL reconstruction (Journal of Orthopaedic Research, 2015). In mouse models of pulmonary fibrosis, GHK-Cu reduced collagen deposition and inflammatory markers through the TGF-β1/Smad2/3 signaling pathway (Life Sciences, 2019). In a mouse model of acute lung injury, GHK-Cu suppressed NF-κB activation and reduced inflammatory cytokines (Oncotarget, 2016).
• In vitro: GHK-Cu upregulates collagen synthesis, decorin, and other extracellular matrix components in cultured fibroblasts, modulates the expression of a large number of human genes broadly implicated in tissue repair and antioxidant defense, and reduces TNF-α-induced secretion of pro-inflammatory mediators (Pickart et al. 2012; Pickart et al. 2015). Gene-expression analyses indicate effects across pathways involved in skin regeneration, inflammation, and oxidative stress (Pickart et al. 2015, Cosmetics).

Known effects

• Skin rejuvenation and collagen synthesis — Moderate evidence; multiple human clinical studies on photoaged skin
• Wound healing acceleration — Moderate evidence; human RCT data (post-laser) and extensive animal models
• Hair growth support — Emerging evidence; mechanistic rationale from follicular studies, limited controlled human data
• Anti-inflammatory activity — Preclinical; NF-κB suppression and TNF-α modulation demonstrated in cell and animal models
• Antioxidant effects — Preclinical; Nrf2 activation and regulation of antioxidant-response-element genes (Pickart et al. 2015)
• Anti-aging at cellular level — Emerging; gene-expression modulation in cultured cells; clinical translation remains limited

Safety signals

Topical GHK-Cu has a long track record in regulated cosmetic products and is generally well tolerated. Skin irritation with topical use is uncommon. The peptidelist safety assessment rates it as Well-Studied for topical applications. Injectable systemic GHK-Cu is a much less standardized category: large controlled safety studies for injected forms have not been published, and systemic copper exposure introduces considerations — including serum copper and ceruloplasmin status — that topical use does not raise. Copper metabolism disorders (such as Wilson's disease) are a recognized contraindication for any copper-delivering agent. The angiogenic activity of GHK-Cu has led clinicians to use caution in patients with active malignancy, given that angiogenesis may support tumor vascularization, though no controlled human data on this risk exists. Formulation-to-formulation variability is a practical safety consideration: actual peptide concentration, copper-loading ratio, and pH stability vary considerably among commercial products that all claim "copper peptide."

Regulatory status

• US: Topical GHK-Cu is regulated as a cosmetic ingredient and is broadly available without prescription in creams, serums, and wound-care products. It has no FDA drug approval for any indication. Injectable compounded preparations have been available through state-licensed compounding pharmacies, but the FDA's ongoing review of peptides eligible for 503A compounding has narrowed that pathway for several peptides; the status of copper peptide in that framework continues to evolve.
• EU / International: Topical GHK-Cu is permitted as a cosmetic ingredient in the EU, UK, Canada, Australia, and most major markets. Systemic or injectable use is not approved by EMA, MHRA, TGA, or Health Canada as a licensed medicine.
• WADA: GHK-Cu is not explicitly listed on the WADA Prohibited List. Topical cosmetic use raises no realistic doping concern. Systemic injectable use may fall under the S0 category, which covers substances not approved by any governmental regulatory authority for human therapeutic use; athletes subject to WADA code should be aware of this ambiguity.

Myths and misconceptions

• "GHK-Cu modulates thousands of genes, so it can reverse virtually any age-related condition." The broad gene-modulation data comes from Connectivity Map analyses showing transcriptional effects in cultured cells. That is mechanistically interesting but does not translate into clinical benefit at the same scale. In controlled human studies, topical GHK-Cu is a competent cosmetic active with measured effects on photoaging and wound healing — not a systemic reversal of aging.
• "Topical copper peptide penetrates deeply enough to remodel the dermis like an injection." GHK-Cu is smaller than most peptide actives (~340 Da) and penetrates the stratum corneum better than larger molecules, but microneedle studies show that no permeation occurs through intact human dermatomed skin without a physical penetration aid (Pharmaceutical Research, 2015). Topical formulations work primarily at the epidermis and upper dermis.
• "Injectable GHK-Cu is as safe as the topical cream." They are different exposure categories. Systemic copper delivery, angiogenic signaling, and sourcing quality are variables that topical skin application does not raise. Injectable GHK-Cu has no FDA approval and essentially no published Phase II or III human safety data.
• "All copper peptide products are equivalent." Actual peptide concentration, copper-loading ratio, pH stability, and delivery vehicle vary dramatically across products that all carry the "copper peptide" label. The published studies showing benefit used specific, characterized formulations.

Open questions

• Controlled injectable human trials: systemic GHK-Cu has essentially no published Phase II or III human data; pharmacokinetics, therapeutic dosing, and clinical endpoints for injected forms rest on extrapolation from topical and animal work.
• Skin penetration quantification in vivo: while in vitro permeation with microneedles is characterized, the fraction of an applied dose reaching viable epidermis and dermis in real-world use across formulation types is not well established.
• Hair growth: the mechanistic rationale around follicular stem cells is plausible, but controlled human trials on scalp application for androgenetic alopecia are limited.
• Head-to-head comparisons: most GHK-Cu trials compare against placebo rather than against established actives such as retinoids or growth factors at equivalent concentrations.
• Long-term safety of chronic systemic exposure: the topical cosmetic track record is reassuring, but rigorous long-term randomized safety data for systemic use is absent.

Related peptides

• AHK-Cu (Ala-His-Lys copper complex) — a copper-binding tripeptide analog with overlapping tissue-remodeling biology, sometimes compared directly to GHK-Cu in dermatologic research.
• Palmitoyl Tripeptide-1 (Pal-GHK) — a palmitoylated derivative of GHK designed for improved stratum-corneum penetration; the palmitoyl chain absent from the GHK sequence is the key structural difference.
• Epithalon — a synthetic tetrapeptide (Ala-Glu-Asp-Gly) with longevity and anti-aging research focus; shares the broader category of short endogenous-sequence peptides studied for age-related tissue decline.